Abbott Submits New FDA Drug Application for Advanced Prostate Cancer Drug, Xinlay? (Atrasentan)

Abbott announced today it has submitted a New Drug Application (NDA) for its oral agent Xinlay? (atrasentan), to the US Food and Drug Administration (FDA) seeking approval of Xinlay for the treatment of metastatic hormone-refractory prostate cancer, an advanced stage of the disease that no longer responds to hormone treatment and has spr...

Continue to Abbott Submits New FDA Drug Application for Advanced Prostate Cancer Drug, Xinlay? (Atrasentan) on Medical News Today.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz